Tribestan film-coated tablets 250 mg 60 pcs.

Pharmacodynamics. A drug of natural origin, obtained using original technology from the aerial part of the plant Tribulus terrestris L. The drug contains mainly steroidal saponins of the furostanol type, among which protodioscin predominates. The mechanism of action of the drug is due to this component.

Protodioscin is metabolized in the body to dehydroepiandrosterone (DHEA), which has beneficial effects on cell membrane permeability, erectile function, cholesterol metabolism, and immunity. Other active furostanol saponins, which are part of the Tribulus terrestris L. plant extract, probably modulate the effect of protodioscin.

Tribestan has a tonic effect and stimulates some functions of the reproductive system. In men, it restores and improves libido and erection. It has a stimulating effect on spermatogenesis, increasing the number of spermatozoa and their motility, and increases testosterone levels. In women, Tribestan also improves libido and stimulates ovulation. It has a beneficial effect on vasomotor manifestations in natural and post-castration climacteric syndrome as a result of its balancing effect on hormonal activity.

Results in healthy volunteers show that Tribestan affects the levels of pituitary-gonadal axis hormones in blood plasma without significantly altering the levels of adrenal hormones and ACTH.

Tribestan has a hypolipidemic effect, and in patients with dyslipoproteinemia it significantly reduces total cholesterol and LDL, without affecting the levels of TG and HDL in blood plasma.

Tribestan has antihypertensive and diuretic effects.

Pharmacokinetics. The active substance protodioscin is rapidly excreted from the blood plasma – within 3 hours its concentration is insignificant. It is excreted mainly with bile. The low percentage of excretion of unchanged protodioscin compared to the dose taken confirms the assumption that it is intensively metabolized in the body.

For the prevention and treatment (monotherapy and complex) of disorders of the reproductive system in men and women. For erectile dysfunction in men – to increase libido, strength and duration of erection. As monotherapy or in complex therapy of certain forms of infertility in men: infertility based on idiopathic oligoasthenoteratospermia (reduction in the number and quality of sperm in the secreted semen); infertility in the absence of improvement in sperm parameters within 1 year after surgery for varicocele; immunologically determined infertility.

Women with climacteric and post-castration syndrome with pronounced neurovegetative and neuropsychiatric manifestations; with endocrine ovarian infertility. With impaired fat metabolism (dyslipoproteinemia) to reduce total cholesterol and LDL.

The tablets are taken orally, after meals.

With reduced libido, impotence and infertility. In men with reduced libido, impotence and infertility, a dosage of 1-2 tablets 3 times a day is recommended. Duration of treatment – at least 90 days. The course of treatment can be repeated until a positive therapeutic effect is obtained.

In women with endocrine infertility, the recommended dosage is 1-2 tablets 3 times a day from the 1st to the 12th day of the menstrual cycle. This course can be repeated periodically until pregnancy occurs.

Dyslipoproteinemia. 2 tablets 3 times a day. Duration of treatment – at least 3 months.

Climacteric and post-castration syndrome in women. 1-2 tablets 3 times a day for 60-90 days. After the condition improves, gradually switch to a maintenance dose – 2 tablets per day for 1-2 years.

Tribestan is contraindicated in:

• hypersensitivity to the components of the drug;
• severe cardiovascular and renal diseases;
• prostate adenoma.

Hypersensitivity reactions are possible. When taken before meals, the drug may have an irritating effect on the gastric mucosa.

When treating women with climacteric syndrome, the transition from therapeutic to maintenance doses should be gradual. After a sharp decrease or cancellation of the effective dose of the drug, a recurrence of the complex of climacteric symptoms is possible.

Pregnancy and breastfeeding. The potential risk to humans is unknown. Due to the lack of clinical studies in pregnant women, Tribestan is contraindicated for use during pregnancy and breastfeeding. If pregnancy is detected, the drug should be discontinued.

Children: The drug is not recommended for use in children under 18 years of age.

The ability to influence the reaction speed when driving vehicles or working with other mechanisms. Does not affect.

The simultaneous use of the drug Tribestan with drugs that stimulate ovulation leads to mutual enhancement of their effects.

Concomitant use of Tribestan with diuretics may enhance the effects of the latter and potentiate the hypotensive effect of antihypertensive drugs.

To date, no cases of overdose with Tribestan have been observed. Symptomatic treatment is indicated in case of ingestion of a large amount of the drug.

In the original packaging to protect from moisture at a temperature not exceeding 25 °C.